tetano
Editor, Senior Moderator
Br J Clin Pharmacol. 2015 Jun 3. doi: 10.1111/bcp.12691. [Epub ahead of print]
[h=1]Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.[/h] Pillai VC[SUP]1[/SUP], Han K[SUP]2[/SUP], Beigi RH[SUP]3[/SUP], Hankins GD[SUP]4[/SUP], Clark S[SUP]4[/SUP], Hebert MF[SUP]5[/SUP], Easterling TR[SUP]5[/SUP], Zajicek A[SUP]6[/SUP], Ren Z[SUP]6[/SUP], Caritis SN[SUP]3[/SUP], Venkataramanan R[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIMS:[/h] Physiological changes in pregnancy are expected to alter the pharmacokinetics of various drugs. The objective of this study was to systematically evaluate the pharmacokinetics of oseltamivir (OS), a drug used in the treatment of influenza during pregnancy.
[h=4]METHODS:[/h] A multicenter steady state pharmacokinetic study of OS was performed in 35 non-pregnant and 29 pregnant women. Plasma concentration-time profiles were analyzed using both non-compartmental and population pharmacokinetic modeling (POP PK) and simulation approaches. A one compartment population pharmacokinetic model with first order absorption and elimination adequately described the pharmacokinetics of OS.
[h=4]RESULTS:[/h] The systemic exposure of oseltamivir carboxylate (OC; active metabolite of OS) was reduced approximately 30(19-36)% (p < 0.001) in pregnant women. Pregnancy significantly (p < 0.001) influenced the clearance (CL/F) and volume of distribution (V/F) of OC. Both non-compartmental and population pharmacokinetic approaches documented approximately 45(23-62)% increase in clearance (CL/F) of OC during pregnancy.
[h=4]CONCLUSION:[/h] Based on the decrease in exposure of the active metabolite, the currently recommended doses of OS may need to be increased modestly in pregnant women in order to achieve comparable exposure as that of non-pregnant women.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] oseltamivir; population pharmacokinetics; pregnancy
PMID: 26040405 [PubMed - as supplied by publisher]
[h=1]Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.[/h] Pillai VC[SUP]1[/SUP], Han K[SUP]2[/SUP], Beigi RH[SUP]3[/SUP], Hankins GD[SUP]4[/SUP], Clark S[SUP]4[/SUP], Hebert MF[SUP]5[/SUP], Easterling TR[SUP]5[/SUP], Zajicek A[SUP]6[/SUP], Ren Z[SUP]6[/SUP], Caritis SN[SUP]3[/SUP], Venkataramanan R[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIMS:[/h] Physiological changes in pregnancy are expected to alter the pharmacokinetics of various drugs. The objective of this study was to systematically evaluate the pharmacokinetics of oseltamivir (OS), a drug used in the treatment of influenza during pregnancy.
[h=4]METHODS:[/h] A multicenter steady state pharmacokinetic study of OS was performed in 35 non-pregnant and 29 pregnant women. Plasma concentration-time profiles were analyzed using both non-compartmental and population pharmacokinetic modeling (POP PK) and simulation approaches. A one compartment population pharmacokinetic model with first order absorption and elimination adequately described the pharmacokinetics of OS.
[h=4]RESULTS:[/h] The systemic exposure of oseltamivir carboxylate (OC; active metabolite of OS) was reduced approximately 30(19-36)% (p < 0.001) in pregnant women. Pregnancy significantly (p < 0.001) influenced the clearance (CL/F) and volume of distribution (V/F) of OC. Both non-compartmental and population pharmacokinetic approaches documented approximately 45(23-62)% increase in clearance (CL/F) of OC during pregnancy.
[h=4]CONCLUSION:[/h] Based on the decrease in exposure of the active metabolite, the currently recommended doses of OS may need to be increased modestly in pregnant women in order to achieve comparable exposure as that of non-pregnant women.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] oseltamivir; population pharmacokinetics; pregnancy
PMID: 26040405 [PubMed - as supplied by publisher]